112 related articles for article (PubMed ID: 2026483)
1. Crisnatol mesylate: phase I dose escalation by extending infusion duration.
Poplin EA; Chabot GG; Tuttle RL; Lucas S; Wargin WA; Baker LH
Invest New Drugs; 1991 Feb; 9(1):41-7. PubMed ID: 2026483
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule.
Cobb PW; Havlin KA; Kuhn JG; Craig JB; Harman GS; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J
Sel Cancer Ther; 1991; 7(2):85-91. PubMed ID: 1754731
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.
Bailey H; Kohler P; Tuttle R; Carbone PP; Hohneker JA; Clendeninn NJ; Wilding G
Invest New Drugs; 1992 Nov; 10(4):279-87. PubMed ID: 1487401
[TBL] [Abstract][Full Text] [Related]
5. Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
Harman GS; Craig JB; Kuhn JG; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J; Tuttle RL; Lucas VS
Cancer Res; 1988 Aug; 48(16):4706-10. PubMed ID: 3396016
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of crisnatol mesylate in patients with ovarian carcinoma.
Smalley RV; Goldstein D; Bulkowski D; Hannon C; Buchler D; Knudsen C; Tuttle RL
Invest New Drugs; 1992 Jul; 10(2):107-12. PubMed ID: 1500264
[TBL] [Abstract][Full Text] [Related]
7. Long-term response to crisnatol mesylate in patients with glioma.
New P; Vokes E; Rogers L; Bazan C; Hohneker J; Eble M; Vilk P
Invest New Drugs; 1997; 15(4):343-52. PubMed ID: 9547677
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
[TBL] [Abstract][Full Text] [Related]
9. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalators.
Havlin KA; Kuhn JG; Craig JB; Weiss GR; Koeller J; Turner JN; Luther JS; Clark G; Bair KW; Wargin W
Anticancer Drugs; 1991 Aug; 2(4):357-63. PubMed ID: 1797191
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
[TBL] [Abstract][Full Text] [Related]
15. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of spirogermanium given daily.
Legha SS; Ajani JA; Bodey GP
J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
19. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
20. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
Rinaldi DA; Burris HA; Dorr FA; Woodworth JR; Kuhn JG; Eckardt JR; Rodriguez G; Corso SW; Fields SM; Langley C
J Clin Oncol; 1995 Nov; 13(11):2842-50. PubMed ID: 7595747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]